SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is surging following a strong earnings report that showcased better-than-expected cloud growth and accelerating AI monetization, effectively calming investor fears regarding high infrastructure spending. The community is actively debating the company's role as a potential market stabilizer, with many bulls cheering the solid guidance while some caution against potential profit-taking at the open.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the UAE's broad authorization of its flagship therapy for multiple indications, a regulatory milestone that underscores the company's expanding global footprint. Investors are actively debating the timing of potential international partnerships and anticipating upcoming earnings, while community sentiment remains split between excitement over clinical momentum and frustration with ongoing share price volatility.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant investor attention following a series of upsized, high-rated ABS deal announcements and strategic insider purchases by the CEO, which have fueled community optimism about the company's AI-driven growth model. Despite broader fintech sector volatility and concerns over macro conditions, many investors are focused on the firm's improved profitability and expanding network volume as key indicators that the stock is currently undervalued relative to its growth potential.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors weigh strong fundamental performance and positive earnings reports against broader sector volatility and heavy selling pressure linked to leveraged equity positions in Asian markets. Community sentiment is deeply polarized, with many market participants debating whether the sharp pullback is a buying opportunity driven by AI-infrastructure demand or a sign of a structural cyclical peak.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending following an earnings report where a top-line revenue beat was overshadowed by weaker-than-expected full-year guidance due to rising fuel costs and soft demand. The community is actively debating the company's turnaround progress and whether the stock's recent price decline reflects genuine fundamental weakness or continued manipulation by institutional traders.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing intense market volatility driven by speculation around an upcoming maintenance trial data readout and persistent short-seller activity. While the company's recent board appointment has sparked debate over the likelihood of an acquisition versus a standalone commercialization strategy, the community remains heavily focused on the clinical potential of VK2735 as a best-in-class obesity treatment.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing intense volatility and massive sell-off pressure, with community sentiment deeply divided between those viewing the decline as a technical capitulation and others warning of a structural bubble bursting. Investors are actively debating the impact of sector-wide memory demand, margin calls on leveraged funds, and speculative overvaluation in a stock that has experienced a dramatic retracement from its previous highs.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is trending as investors weigh its aggressive 'Fastlane 2030' turnaround plan, which targets billions in cost savings and a pivot back toward profitable core brands like Jeep and Ram, against concerns over weak North American margins and intense global EV competition. Community sentiment is deeply divided, with many traders viewing the stock as a heavily undervalued cyclic play ripe for accumulation, while skeptics point to ongoing inventory bloat and recent negative earnings headlines as signals of deeper structural risk.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing significant volatility as investors weigh robust earnings from major tech giants against broader macroeconomic concerns, including rising bond yields and geopolitical tensions. Market participants are actively debating whether the recent market pullback represents a healthy buying opportunity or the beginning of a deeper correction driven by cooling economic growth.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is facing intense volatility as investors rotate out of high-valuation AI and semiconductor stocks, with the share price retracting significantly from recent highs due to concerns over stretched valuations and supply chain constraints. While the community remains divided, with some investors seizing the dip as a long-term accumulation opportunity based on Arm's foundational role in AI compute, others are actively warning of a potential bubble and criticizing the influence of analyst price target revisions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?

NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade

The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects

Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today? 

Equity

Investors rewarded strong execution, improving profits and raised outlook.


NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?

The medical device maker, which develops Tumor Treating Fields (TTFields) therapy for cancer, said Q2 marked its strongest performance to date. 


Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results

US stocks lower, Dow down 0.92%, NASDAQ 2.03% decline. T-Mobile stock falls 5%. NVE Corp up 38%, Novocure up 25%, Cleveland-Cliffs up 19%read more...

NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of +56.67% and +5.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Novocure Reports Second Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields...

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, the United Kingdom.

NovoCure Ltd

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVCRNovoCure Ltd

Fundamentals

Latest NVCR News